Supplementary Materials

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Characterization of TMPs and TMPs-MTX.
  • Fig. S2. Effect of TMPs on tumor cell viability and invasion in vitro.
  • Fig. S3. Cellular uptake and cytotoxicity of TMPs-MTX and the interaction of TMPs-MTX with immune cells.
  • Fig. S4. Biodistribution and internalization of TMPs-MTX in vivo.
  • Fig. S5. Analysis of immune infiltrates in pleural tumor and MPE of LLC cell–induced murine MPE models after ATMP-MTX treatment.
  • Fig. S6. Immune cell components in peripheral blood after ATMP-MTX treatment and macrophage depletion by clodronate liposome treatment.
  • Fig. S7. ATMP-MTX treatment in advanced lung cancer patients with MPE.
  • Fig. S8. Immune cell components in peripheral blood and cytokine concentrations in MPE of lung cancer patients treated with ATMPs-MTX.
  • Table S1. Patient demographics.
  • Table S2. Patient adverse events related to ATMP-MTX treatment.
  • References (57–60)

[Download PDF]